Skip to main content
SpringerLink
Log in

IGF-1 Cellular Action and its Relationship to Cancer: Evidence from in Vitro and in Vivo Studies

  • Chapter
  • First Online:
Insulin-like Growth Factors and Cancer

Part of the book series: Cancer Drug Discovery and Development ((CDD&D))

Abstract

Insulin-like growth factors (IGFs), which include insulin-like growth factor I (IGF-I) and insulin-like growth factor II (IGF-II) are mitogenic and anti-apoptotic growth factors that regulate cellular proliferation, differentiation and cell death. The mitogenic and anti-apoptotic properties of IGF-I and IGF-II affect both normal and cancerous cells. The effects of the IGFs on cell growth and apoptosis are ­mediated through binding to a tyrosine kinase receptor, the insulin-like growth ­factor-I receptor (IGF-IR). The IGF-IIR (the cation-independent mannose-6-phosphate receptor – M6P-R) is a single transmembrane glycoprotein that mediates the uptake and processing of M6P-containing cytokines, enzymes and peptide hormones and is involved in diverse functions related to lysosome biogenesis. IGF-II also binds the insulin receptor isoform-A (IR-A), with high affinity and can trigger mitogenic activity. IR and IGF-IR form hybrid heterodimeric receptors that bind insulin and IGFs. However, the role of the hybrid receptors in physiology and ­carcinogenesis is not fully understood and remains an area of active investigation.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Abramovitch, S., T. Glaser, et al. (2003). “BRCA1-Sp1 interactions in transcriptional regulation of the IGF-IR gene.” FEBS Lett 541(1–3): 149–54.

    Article  PubMed  CAS  Google Scholar 

  • Allen, G.W., C. Saba et al. (2007). “Insulin-like growth factor-I receptor signaling blockade ­combined with radiation.” Cancer Res 67(3):1155–62.

    Article  PubMed  CAS  Google Scholar 

  • Allen, N. E., T. J. Key, et al. (2007). “Serum insulin-like growth factor (IGF)-I and IGF-binding protein-3 concentrations and prostate cancer risk: results from the European Prospective Investigation into Cancer and Nutrition.” Cancer Epidemiol Biomarkers Prev 16(6): 1121–7.

    Article  PubMed  CAS  Google Scholar 

  • Andre, F., V. Rigot, et al. (1999). “Integrins and E-cadherin cooperate with IGF-I to induce migration of epithelial colonic cells.” Int J Cancer 83(4): 497–505.

    Article  PubMed  CAS  Google Scholar 

  • Anzo, M., L. J. Cobb, et al. (2008). “Targeted deletion of hepatic Igf1 in TRAMP mice leads to dramatic alterations in the circulating insulin-like growth factor axis but does not reduce tumor progression.” Cancer Res 68(9): 3342–9.

    Article  PubMed  CAS  Google Scholar 

  • Baglietto, L., D. R. English, et al. (2007). “Circulating insulin-like growth factor-I and binding protein-3 and the risk of breast cancer.” Cancer Epidemiol Biomarkers Prev 16(4): 763–8.

    Article  PubMed  CAS  Google Scholar 

  • Balaram, S. K., D. K. Agrawal, et al. (1999). “Insulin like growth factor-1 activates nuclear factor-kappaB and increases transcription of the intercellular adhesion molecule-1 gene in endothelial cells.” Cardiovasc Surg 7(1): 91–7.

    Article  PubMed  CAS  Google Scholar 

  • Barnes, C. J., K. Ohshiro, et al. (2007). “Insulin-like growth factor receptor as a therapeutic target in head and neck cancer.” Clin Cancer Res 13(14): 4291–9.

    Article  PubMed  CAS  Google Scholar 

  • Baserga R., F. Peruzzi et al (2003) “The IGF-1 receptor in cancer biology.” Int J Cancer 107(6):873–7.

    Article  PubMed  CAS  Google Scholar 

  • Bauer, T. W., W. Liu, et al. (2005). “Targeting of urokinase plasminogen activator receptor in human pancreatic carcinoma cells inhibits c-Met- and insulin-like growth factor-I receptor-mediated migration and invasion and orthotopic tumor growth in mice.” Cancer Res 65(17): 7775–81.

    PubMed  CAS  Google Scholar 

  • Baxter, R. C. (1988). “Characterization of the acid-labile subunit of the growth hormone-dependent insulin-like growth factor binding protein complex.” J Clin Endocrinol Metab 67(2): 265–72.

    Article  PubMed  CAS  Google Scholar 

  • Bentov, I., D. LeRoith, et al. (2003). “The WT1 Wilms’ tumor suppressor gene: a novel target for insulin-like growth factor-I action.” Endocrinology 144(10): 4276–9.

    Article  PubMed  CAS  Google Scholar 

  • Berfield, A. K., D. Spicer, et al. (1997). “Insulin-like growth factor I (IGF-I) induces unique effects in the cytoskeleton of cultured rat glomerular mesangial cells.” J Histochem Cytochem 45(4): 583–93.

    Article  PubMed  CAS  Google Scholar 

  • Bergsland E.K. (2004). “Update on clinical trials targeting vascular endothelial growth factor in cancer.” Am J Health Syst Pharm 61(21 Suppl 5): S12–20.

    PubMed  CAS  Google Scholar 

  • Bjorndahl, M., R. Cao, et al. (2005). “Insulin-like growth factors 1 and 2 induce lymphangiogenesis in vivo.” Proc Natl Acad Sci USA 102(43): 15593–8.

    Article  PubMed  CAS  Google Scholar 

  • Blum G., A. Gazit et al. (2000). “Substrate competitive inhibitors of IGF-1 receptor kinase.” Biochemistry 39(51):15705–12.

    Article  PubMed  CAS  Google Scholar 

  • Bohlke, K., D. W. Cramer, et al. (1998). “Insulin-like growth factor-I in relation to premenopausal ductal carcinoma in situ of the breast.” Epidemiology 9(5): 570–3.

    Article  PubMed  CAS  Google Scholar 

  • Bredin, C. G., Z. Liu, et al. (2003). “Growth factor-enhanced expression and activity of matrix metalloproteases in human non-small cell lung cancer cell lines.” Anticancer Res 23(6C): 4877–84.

    Google Scholar 

  • Bruning, P. F., J. Van Doorn, et al. (1995). “Insulin-like growth-factor-binding protein 3 is decreased in early-stage operable pre-menopausal breast cancer.” Int J Cancer 62(3): 266–70.

    Article  PubMed  CAS  Google Scholar 

  • Burgering, B. M. and R. H. Medema (2003). “Decisions on life and death: FOXO Forkhead transcription factors are in command when PKB/Akt is off duty.” J Leukoc Biol 73(6): 689–701.

    Article  PubMed  CAS  Google Scholar 

  • Call, K. M., T. Glaser, et al. (1990). “Isolation and characterization of a zinc finger polypeptide gene at the human chromosome 11 Wilms’ tumor locus.” Cell 60(3): 509–20.

    Article  PubMed  CAS  Google Scholar 

  • Cano, A., M. A. Perez-Moreno, et al. (2000). “The transcription factor snail controls epithelial-mesenchymal transitions by repressing E-cadherin expression.” Nat Cell Biol 2(2): 76–83.

    Article  PubMed  CAS  Google Scholar 

  • Cantley, L. C. and B. G. Neel (1999). “New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway.” Proc Natl Acad Sci USA 96(8): 4240–5.

    Article  PubMed  CAS  Google Scholar 

  • Cats, A., R. P. Dullaart, et al. (1996). “Increased epithelial cell proliferation in the colon of patients with acromegaly.” Cancer Res 56(3): 523–6.

    PubMed  CAS  Google Scholar 

  • Ceacareanu, A. C., B. Ceacareanu, et al. (2006). “Nitric oxide attenuates IGF-I-induced aortic smooth muscle cell motility by decreasing Rac1 activity: essential role of PTP-PEST and p130cas.” Am J Physiol Cell Physiol 290(4): C1263–70.

    Article  PubMed  CAS  Google Scholar 

  • Chan, J. M., M. J. Stampfer, et al. (1998). “Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study.” Science 279(5350): 563–6.

    Article  PubMed  CAS  Google Scholar 

  • Chattopadhyay, S. and V. I. Shubayev (2009). “MMP-9 controls Schwann cell proliferation and phenotypic remodeling via IGF-1 and ErbB receptor-mediated activation of MEK/ERK pathway.” Glia 57(12): 1316–25.

    Article  PubMed  Google Scholar 

  • Che, W., N. Lerner-Marmarosh, et al. (2002). “Insulin-like growth factor-1 enhances inflammatory responses in endothelial cells: role of Gab1 and MEKK3 in TNF-alpha-induced c-Jun and NF-kappaB activation and adhesion molecule expression.” Circ Res 90(11): 1222–30.

    Article  PubMed  CAS  Google Scholar 

  • Chen, C., S. K. Lewis, et al. (2005). “Prostate carcinoma incidence in relation to prediagnostic circulating levels of insulin-like growth factor I, insulin-like growth factor binding protein 3, and insulin.” Cancer 103(1): 76–84.

    Article  PubMed  CAS  Google Scholar 

  • Chen, Y. W., V. Boyartchuk, et al. (2009). “Differential roles of insulin-like growth factor receptor- and insulin receptor-mediated signaling in the phenotypes of hepatocellular carcinoma cells.” Neoplasia 11(9): 835–45.

    PubMed  CAS  Google Scholar 

  • Cheng, H. L., M. L. Steinway, et al. (2000). “GTPases and phosphatidylinositol 3-kinase are critical for insulin-like growth factor-I-mediated Schwann cell motility.” J Biol Chem 275(35): 27197–204.

    PubMed  CAS  Google Scholar 

  • Chernicky, C. L., H. Tan, et al. (2002). “Treatment of murine breast cancer cells with antisense RNA to the type I insulin-like growth factor receptor decreases the level of plasminogen activator transcripts, inhibits cell growth in vitro, and reduces tumorigenesis in vivo.” Mol Pathol 55(2): 102–9.

    Article  PubMed  CAS  Google Scholar 

  • Chinnadurai, G. (2002). “CtBP, an unconventional transcriptional corepressor in development and oncogenesis.” Mol Cell 9(2): 213–24.

    Article  PubMed  CAS  Google Scholar 

  • Christofori, G., P. Naik, et al. (1995). “Deregulation of both imprinted and expressed alleles of the insulin-like growth factor 2 gene during beta-cell tumorigenesis.” Nat Genet 10(2): 196–201.

    Article  PubMed  CAS  Google Scholar 

  • Culig, Z., A. Hobisch, et al. (1995). “Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor and epidermal growth factor.” Eur Urol 27 Suppl 2: 45–7.

    PubMed  Google Scholar 

  • D’Ambrosio C., A.A. Ferber et al. (1996). “Soluble insulin-like growth factor I receptor that induces apoptosis of tumor cells in vivo and inhibits tumorigenesis.” Cancer Res 56(17): 4013–20.

    PubMed  Google Scholar 

  • Del Giudice, M. E., I. G. Fantus, et al. (1998). “Insulin and related factors in premenopausal breast cancer risk.” Breast Cancer Res Treat 47(2): 111–20.

    Article  PubMed  Google Scholar 

  • Delling, U., J. Tureckova, et al. (2000). “A calcineurin-NFATc3-dependent pathway regulates skeletal muscle differentiation and slow myosin heavy-chain expression.” Mol Cell Biol 20(17): 6600–11.

    Article  PubMed  CAS  Google Scholar 

  • Desbois-Mouthon C., A. Baron et al. (2009). “Insulin-like growth factor-1 receptor inhibition induces a resistance mechanism via the epidermal growth factor receptor/HER3/AKT signaling pathway: rational basis for cotargeting insulin-like growth factor-1 receptor and epidermal growth factor receptor in hepatocellular carcinoma.” Clin Cancer Res 15(17):5445–56.

    Article  PubMed  CAS  Google Scholar 

  • Di Cristofano, A. and P. P. Pandolfi (2000). “The multiple roles of PTEN in tumor suppression.” Cell 100(4): 387–90.

    Article  PubMed  Google Scholar 

  • DiGiovanni, J., K. Kiguchi, et al. (2000). “Deregulated expression of insulin-like growth factor 1 in prostate epithelium leads to neoplasia in transgenic mice.” Proc Natl Acad Sci USA 97(7): 3455–60.

    Article  PubMed  CAS  Google Scholar 

  • Dirx, M.J., P.A. van den Brandt et al. (1999). Diet in adolescence and the risk of breast cancer: results of the Netherlands Cohort Study. Cancer Causes Control 10(3): 189–99.

    Article  PubMed  CAS  Google Scholar 

  • Dirx, M.J., M.P. Zeegers et al. (2003). “Energy restriction and the risk of spontaneous mammary tumors in mice: a meta-analysis.” Int Journal of Cancer 106(5): 766–70.

    Article  CAS  Google Scholar 

  • Doerr, M. E. and J. I. Jones (1996). “The roles of integrins and extracellular matrix proteins in the insulin-like growth factor I-stimulated chemotaxis of human breast cancer cells.” J Biol Chem 271(5): 2443–7.

    Article  PubMed  CAS  Google Scholar 

  • Dominici, F. P., D. P. Argentino, et al. (2005). “Influence of the crosstalk between growth hormone and insulin signalling on the modulation of insulin sensitivity.” Growth Horm IGF Res 15(5): 324–36.

    Article  PubMed  CAS  Google Scholar 

  • Dunn, S. E., F. W. Kari, et al. (1997). “Dietary restriction reduces insulin-like growth factor I levels, which modulates apoptosis, cell proliferation, and tumor progression in p53-deficient mice.” Cancer Res 57(21): 4667–72.

    PubMed  CAS  Google Scholar 

  • Dunn, S. E., J. V. Torres, et al. (2000). “The insulin-like growth factor-1 elevates urokinase-type plasminogen activator-1 in human breast cancer cells: a new avenue for breast cancer therapy.” Mol Carcinog 27(1): 10–7.

    Article  PubMed  CAS  Google Scholar 

  • Dunn, S. E., J. V. Torres, et al. (2001). “Up-regulation of urokinase-type plasminogen activator by insulin-like growth factor-I depends upon phosphatidylinositol-3 kinase and mitogen-activated protein kinase kinase.” Cancer Res 61(4): 1367–74.

    PubMed  CAS  Google Scholar 

  • Dupont, J., M. Karas, et al. (2000). “The potentiation of estrogen on insulin-like growth factor I action in MCF-7 human breast cancer cells includes cell cycle components.” J Biol Chem 275(46): 35893–901.

    Article  PubMed  CAS  Google Scholar 

  • Dupont, J., A. Pierre, et al. (2003). “The insulin-like growth factor axis in cell cycle progression.” Horm Metab Res 35(11–12): 740–50.

    PubMed  CAS  Google Scholar 

  • Earl, T.M., I.B. Nicoud et al. (2009). “Silencing of TLR4 decreases liver tumor burden in a murine model of colorectal metastasis and hepatic steatosis.” Ann Surg Oncol 4:1043–50.

    Article  Google Scholar 

  • Elia, L., R. Contu, et al. (2009). “Reciprocal regulation of microRNA-1 and insulin-like growth factor-1 signal transduction cascade in cardiac and skeletal muscle in physiological and pathological conditions.” Circulation 120(23): 2377–85.

    Article  PubMed  CAS  Google Scholar 

  • Etienne-Manneville, S. and A. Hall (2002). “Rho GTPases in cell biology.” Nature 420(6916): 629–35.

    Article  PubMed  CAS  Google Scholar 

  • Figueroa, J. A., S. De Raad, et al. (2001). “Gene expression of insulin-like growth factors and receptors in neoplastic prostate tissues: correlation with clinico-pathological parameters.” Cancer Invest 19(1): 28–34.

    Article  PubMed  CAS  Google Scholar 

  • Finlay, D. and D. Cantrell (2010). “Phosphoinositide 3-kinase and the mammalian target of rapamycin pathways control T cell migration.” Ann N Y Acad Sci 1183: 149–57.

    Article  PubMed  CAS  Google Scholar 

  • Fowler, C.A., C.M. Perks et al (2000). “Insulin-like growth factor binding protein-3 (IGFBP-3) potentiates paclitaxel-induced apoptosis in human breast cancer cells.” Int J Cancer 88(3):448–53.

    Article  PubMed  CAS  Google Scholar 

  • Friedl, P. (2004). “Prespecification and plasticity: shifting mechanisms of cell migration.” Curr Opin Cell Biol 16(1): 14–23.

    Article  PubMed  CAS  Google Scholar 

  • Friedl, P., Y. Hegerfeldt, et al. (2004). “Collective cell migration in morphogenesis and cancer.” Int J Dev Biol 48(5–6): 441–9.

    Article  PubMed  CAS  Google Scholar 

  • Fukuda, R., K. Hirota, et al. (2002). “Insulin-like growth factor 1 induces hypoxia-inducible factor 1-mediated vascular endothelial growth factor expression, which is dependent on MAP kinase and phosphatidylinositol 3-kinase signaling in colon cancer cells.” J Biol Chem 277(41): 38205–11.

    Article  PubMed  CAS  Google Scholar 

  • Furlanetto, R. W., S. E. Harwell, et al. (1994). “Insulin-like growth factor-I induces cyclin-D1 expression in MG63 human osteosarcoma cells in vitro.” Mol Endocrinol 8(4): 510–7.

    Article  PubMed  CAS  Google Scholar 

  • Furundzija, V., J. Fritzsche, et al. (2010). “IGF-1 increases macrophage motility via PKC/p38-dependent alphavbeta3-integrin inside-out signaling.” Biochem Biophys Res Commun 394(3): 786–91.

    Article  PubMed  CAS  Google Scholar 

  • Gallicchio, M. A., C. Kaun, et al. (2003). “Urokinase type plasminogen activator receptor is involved in insulin-like growth factor-induced migration of rhabdomyosarcoma cells in vitro.” J Cell Physiol 197(1): 131–8.

    Article  PubMed  CAS  Google Scholar 

  • Galvan, V., A. Logvinova, et al. (2003). “Type 1 insulin-like growth factor receptor (IGF-IR) signaling inhibits apoptosis signal-regulating kinase 1 (ASK1).” J Biol Chem 278(15): 13325–32.

    Article  PubMed  CAS  Google Scholar 

  • Gariboldi, M.B., R. Ravizza et al. (2010). “The IGFR1 inhibitor NVP-AEW541 disrupts a pro-survival and pro-angiogenic IGF-STAT3-HIF1 pathway in human glioblastoma cells.” Biochem Pharmacol. In press.

    Google Scholar 

  • Gerald, W. L., J. Rosai, et al. (1995). “Characterization of the genomic breakpoint and chimeric transcripts in the EWS-WT1 gene fusion of desmoplastic small round cell tumor.” Proc Natl Acad Sci USA 92(4): 1028–32.

    Article  PubMed  CAS  Google Scholar 

  • Gessler, M., A. Poustka, et al. (1990). “Homozygous deletion in Wilms tumours of a zinc-finger gene identified by chromosome jumping.” Nature 343(6260): 774–8.

    Article  PubMed  CAS  Google Scholar 

  • Giannelli, G., J. Falk-Marzillier, et al. (1997). “Induction of cell migration by matrix metalloprotease-2 cleavage of laminin-5.” Science 277(5323): 225–8.

    Article  PubMed  CAS  Google Scholar 

  • Giovannucci, E., M. N. Pollak, et al. (2000). “A prospective study of plasma insulin-like growth factor-1 and binding protein-3 and risk of colorectal neoplasia in women.” Cancer Epidemiol Biomarkers Prev 9(4): 345–9.

    PubMed  CAS  Google Scholar 

  • Giovannucci, E. (2001). “Insulin, insulin-like growth factors and colon cancer: a review of the evidence.” J Nutr 131(11 Suppl): 3109S-20S.

    PubMed  CAS  Google Scholar 

  • Girnita, A., C. All-Ericsson, et al. (2006). “The insulin-like growth factor-I receptor inhibitor picropodophyllin causes tumor regression and attenuates mechanisms involved in invasion of uveal melanoma cells.” Clin Cancer Res 12(4): 1383–91.

    Article  PubMed  CAS  Google Scholar 

  • Goetsch, L., A. Gonzalez et al. (2005). “A recombinant humanized anti-insulin-like growth factor receptor type I antibody (h7C10) enhances the antitumor activity of vinorelbine and anti-epidermal growth factor receptor therapy against human cancer xenografts.” Intl J Cancer 113(2):316–28.

    Article  CAS  Google Scholar 

  • Graham, T. R., H. E. Zhau, et al. (2008). “Insulin-like growth factor-I-dependent up-regulation of ZEB1 drives epithelial-to-mesenchymal transition in human prostate cancer cells.” Cancer Res 68(7): 2479–88.

    Article  PubMed  CAS  Google Scholar 

  • Granata, R., L. Trovato et al. (2004). “Dual effects of IGFBP-3 on endothelial cell apoptosis and survival: involvement of the sphingolipid signaling pathways.” FASEB J 18(12):1456–8. In press.

    Google Scholar 

  • Grooteclaes, M. L. and S. M. Frisch (2000). “Evidence for a function of CtBP in epithelial gene regulation and anoikis.” Oncogene 19(33): 3823–8.

    Article  PubMed  CAS  Google Scholar 

  • Gumbiner, B. M. (2000). “Regulation of cadherin adhesive activity.” J Cell Biol 148(3): 399–404.

    Article  PubMed  CAS  Google Scholar 

  • Gunter, M. J., D. R. Hoover, et al. (2009). “Insulin, insulin-like growth factor-I, and risk of breast cancer in postmenopausal women.” J Natl Cancer Inst 101(1): 48–60.

    PubMed  CAS  Google Scholar 

  • Guo, Y. S., S. Narayan, et al. (1992). “Characterization of insulinlike growth factor I receptors in human colon cancer.” Gastroenterology 102(4 Pt 1): 1101–8.

    PubMed  CAS  Google Scholar 

  • Hadsell, D. L., K. L. Murphy, et al. (2000). “Cooperative interaction between mutant p53 and des(1–3)IGF-I accelerates mammary tumorigenesis.” Oncogene 19(7): 889–98.

    Article  PubMed  CAS  Google Scholar 

  • Hägerstrand, D., M.B. Lindh et al. (2010). “PI3K/PTEN/Akt pathway status affects the sensitivity of high-grade glioma cell cultures to the insulin-like growth factor-1 receptor inhibitor NVP-AEW541.” Neuro Oncol. In press.

    Google Scholar 

  • Hamelers, I. H., R. F. van Schaik, et al. (2002). “Insulin-like growth factor I triggers nuclear accumulation of cyclin D1 in MCF-7S breast cancer cells.” J Biol Chem 277(49): 47645–52.

    Article  PubMed  CAS  Google Scholar 

  • Hankinson, S. E., W. C. Willett, et al. (1998). “Circulating concentrations of insulin-like growth factor-I and risk of breast cancer.” Lancet 351(9113): 1393–6.

    Article  PubMed  CAS  Google Scholar 

  • Harding, H. P. and D. Ron (2002). “Endoplasmic reticulum stress and the development of diabetes: a review.” Diabetes 51 Suppl 3: S455–61.

    Article  PubMed  CAS  Google Scholar 

  • Harvey, K. F., N. L. Harvey, et al. (1998). “Caspase-mediated cleavage of the ubiquitin-protein ligase Nedd4 during apoptosis.” J Biol Chem 273(22): 13524–30.

    Article  PubMed  CAS  Google Scholar 

  • Hayashi, M., M. Sakata, et al. (2005). “Up-regulation of c-met protooncogene product expression through hypoxia-inducible factor-1alpha is involved in trophoblast invasion under low-oxygen tension.” Endocrinology 146(11): 4682–9.

    Article  PubMed  CAS  Google Scholar 

  • Häyry, P., M. Myllärniemi et al. (1995). “Stabile D-peptide analog of insulin-like growth factor-1 inhibits smooth muscle cell proliferation after carotid ballooning injury in the rat.” FASEB J 9(13):1336–44.

    PubMed  Google Scholar 

  • Heck, S., F. Lezoualc’h, et al. (1999). “Insulin-like growth factor-1-mediated neuroprotection against oxidative stress is associated with activation of nuclear factor kappaB.” J Biol Chem 274(14): 9828–35.

    Article  PubMed  CAS  Google Scholar 

  • Hellawell, G. O., G. D. Turner, et al. (2002). “Expression of the type 1 insulin-like growth factor receptor is up-regulated in primary prostate cancer and commonly persists in metastatic disease.” Cancer Res 62(10): 2942–50.

    PubMed  CAS  Google Scholar 

  • Hemers, E., C. Duval, et al. (2005). “Insulin-like growth factor binding protein-5 is a target of matrix metalloproteinase-7: implications for epithelial-mesenchymal signaling.” Cancer Res 65(16): 7363–9.

    Article  PubMed  CAS  Google Scholar 

  • Hong, S. H., J. Briggs, et al. (2009). “Murine osteosarcoma primary tumour growth and metastatic progression is maintained after marked suppression of serum insulin-like growth factor I.” Int J Cancer 124(9): 2042–9.

    Article  PubMed  CAS  Google Scholar 

  • Horiuchi, A., T. Imai, et al. (2003). “Up-regulation of small GTPases, RhoA and RhoC, is associated with tumor progression in ovarian carcinoma.” Lab Invest 83(6): 861–70.

    PubMed  CAS  Google Scholar 

  • Hotamisligil, G. S. (2006). “Inflammation and metabolic disorders.” Nature 444(7121): 860–7.

    Article  PubMed  CAS  Google Scholar 

  • Humphries, M. J. (2000). “Integrin structure.” Biochem Soc Trans 28(4): 311–39.

    Article  PubMed  CAS  Google Scholar 

  • Hursting, S. D., B. R. Switzer, et al. (1993). “The growth hormone: insulin-like growth factor 1 axis is a mediator of diet restriction-induced inhibition of mononuclear cell leukemia in Fischer rats.” Cancer Res 53(12): 2750–7.

    PubMed  CAS  Google Scholar 

  • Iwamura, M., P. M. Sluss, et al. (1993). “Insulin-like growth factor I: action and receptor characterization in human prostate cancer cell lines.” Prostate 22(3): 243–52.

    Article  PubMed  CAS  Google Scholar 

  • Janssen, J. A., M. F. Wildhagen, et al. (2004). “Circulating free insulin-like growth factor (IGF)-I, total IGF-I, and IGF binding protein-3 levels do not predict the future risk to develop prostate cancer: results of a case-control study involving 201 patients within a population-based screening with a 4-year interval.” J Clin Endocrinol Metab 89(9): 4391–6.

    Article  PubMed  CAS  Google Scholar 

  • Jenkins, P. J., P. D. Fairclough, et al. (1997). “Acromegaly, colonic polyps and carcinoma.” Clin Endocrinol (Oxf) 47(1): 17–22.

    Article  CAS  Google Scholar 

  • Kaaks, R., P. Toniolo, et al. (2000). “Serum C-peptide, insulin-like growth factor (IGF)-I, IGF-binding proteins, and colorectal cancer risk in women.” J Natl Cancer Inst 92(19): 1592–600.

    Article  PubMed  CAS  Google Scholar 

  • Karnieli, E., H. Werner, et al. (1996). “The IGF-I receptor gene promoter is a molecular target for the Ewing’s sarcoma-Wilms’ tumor 1 fusion protein.” J Biol Chem 271(32): 19304–9.

    Article  PubMed  CAS  Google Scholar 

  • Key, T. J., P. N. Appleby, A. W. Roddam, (2010). Endogenous Hormones and Breast Cancer Collaborative Group. “Insulin-like growth factor 1 (IGF1), IGF binding protein 3 (IGFBP3), and breast ­cancer risk: pooled individual data analysis of 17 prospective studies.” Lancet Oncol 11(6): 530–42.

    Article  PubMed  CAS  Google Scholar 

  • Kiaris, H., M. Koutsilieris et al. (2003). “Growth hormone-releasing hormone and extra- pituitary tumorigenesis: therapeutic and diagnostic applications of growth hormone-releasing hormone antagonists.” Expert Opin Investig Drugs 12(8):1385–94.

    Article  PubMed  CAS  Google Scholar 

  • Kiely, P. A., D. O’Gorman, et al. (2006). “Insulin-like growth factor I controls a mutually exclusive association of RACK1 with protein phosphatase 2A and beta1 integrin to promote cell migration.” Mol Cell Biol 26(11): 4041–51.

    Article  PubMed  CAS  Google Scholar 

  • Kim, H. J., B. C. Litzenburger, et al. (2007). “Constitutively active type I insulin-like growth factor receptor causes transformation and xenograft growth of immortalized mammary epithelial cells and is accompanied by an epithelial-to-mesenchymal transition mediated by NF-kappaB and snail.” Mol Cell Biol 27(8): 3165–75.

    Article  PubMed  CAS  Google Scholar 

  • Kjoller, L. and A. Hall (1999). “Signaling to Rho GTPases.” Exp Cell Res 253(1): 166–79.

    Article  PubMed  CAS  Google Scholar 

  • Kleer, C. G., K. L. van Golen, et al. (2002). “Characterization of RhoC expression in benign and malignant breast disease: a potential new marker for small breast carcinomas with metastatic ability.” Am J Pathol 160(2): 579–84.

    Article  PubMed  CAS  Google Scholar 

  • Kleinberg, D. L., M. Feldman, et al. (2000). “IGF-I: an essential factor in terminal end bud formation and ductal morphogenesis.” J Mammary Gland Biol Neoplasia 5(1): 7–17.

    Article  PubMed  CAS  Google Scholar 

  • Klemke, R. L., M. Yebra, et al. (1994). “Receptor tyrosine kinase signaling required for integrin alpha v beta 5-directed cell motility but not adhesion on vitronectin.” J Cell Biol 127(3): 859–66.

    Article  PubMed  CAS  Google Scholar 

  • Knudsen, K. A., A. P. Soler, et al. (1995). “Interaction of alpha-actinin with the cadherin/catenin cell-cell adhesion complex via alpha-catenin.” J Cell Biol 130(1): 67–77.

    Article  PubMed  CAS  Google Scholar 

  • Lacey, J. V., Jr., A. W. Hsing, et al. (2001). “Null association between insulin-like growth factors, insulin-like growth factor-binding proteins, and prostate cancer in a prospective study.” Cancer Epidemiol Biomarkers Prev 10(10): 1101–2.

    PubMed  CAS  Google Scholar 

  • Lang, S. A., C. Moser, et al. (2007). “Targeting heat shock protein 90 in pancreatic cancer impairs insulin-like growth factor-I receptor signaling, disrupts an interleukin-6/signal-transducer and activator of transcription 3/hypoxia-inducible factor-1alpha autocrine loop, and reduces orthotopic tumor growth.” Clin Cancer Res 13(21): 6459–68.

    Article  PubMed  CAS  Google Scholar 

  • Laughner, E., P. Taghavi, et al. (2001). “HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1alpha (HIF-1alpha) synthesis: novel mechanism for HIF-1-mediated vascular endothelial growth factor expression.” Mol Cell Biol 21(12): 3995–4004.

    Article  PubMed  CAS  Google Scholar 

  • Lavoie, J. N., G. L’Allemain, et al. (1996). “Cyclin D1 expression is regulated positively by the p42/p44MAPK and negatively by the p38/HOGMAPK pathway.” J Biol Chem 271(34): 20608–16.

    Article  PubMed  CAS  Google Scholar 

  • LeRoith, D. (2007). “Insulin glargine and receptor-mediated signalling: clinical implications in treating type 2 diabetes.” Diabetes Metab Res Rev 23(8): 593–9.

    Article  PubMed  CAS  Google Scholar 

  • Lee, A. V., J. G. Jackson, et al. (1999). “Enhancement of insulin-like growth factor signaling in human breast cancer: estrogen regulation of insulin receptor substrate-1 expression in vitro and in vivo.” Mol Endocrinol 13(5): 787–96.

    Article  PubMed  CAS  Google Scholar 

  • Lee, D.Y., H.K. Yee et al. (2002). “Enhanced expression of insulin-like growth factor binding protein-3 sensitizes the growth inhibitory effect of anticancer drugs in gastric cancer cells.” Biochem Biophys Res Commun 294(2): 480–6.

    Article  PubMed  CAS  Google Scholar 

  • Leger, B., R. Cartoni, et al. (2006). “Akt signalling through GSK-3beta, mTOR and Foxo1 is involved in human skeletal muscle hypertrophy and atrophy.” J Physiol 576(Pt 3): 923–33.

    Article  PubMed  CAS  Google Scholar 

  • Li, S., D. Zhang, et al. (2009). “The IGF-I receptor can alter the matrix metalloproteinase repertoire of tumor cells through transcriptional regulation of PKC-{alpha}.” Mol Endocrinol 23(12): 2013–25.

    Article  PubMed  CAS  Google Scholar 

  • Lip P.L., S. Chatterjee et al. (2004). “Plasma vascular endothelial growth factor, angiopoietin-2, and soluble angiopoietin receptor tie-2 in diabetic retinopathy: effects of laser photocoagulation and angiotensin receptor blockade.” Br J Opthamol 88(12):1543–6.

    Article  CAS  Google Scholar 

  • Litzenburger, B.C., H.J. Kim et al. (2009). “BMS-536924 reverses IGF-IR-induced transformation of mammary epithelial cells and causes growth inhibition and polarization of MCF7 cells.” Clin Cancer Res 15(1):226–37.

    Article  PubMed  CAS  Google Scholar 

  • Lopez, T. and D. Hanahan (2002). “Elevated levels of IGF-1 receptor convey invasive and metastatic capability in a mouse model of pancreatic islet tumorigenesis.” Cancer Cell 1(4): 339–53.

    Article  PubMed  CAS  Google Scholar 

  • Lynch, L., P. I. Vodyanik, et al. (2005). “Insulin-like growth factor I controls adhesion strength mediated by alpha5beta1 integrins in motile carcinoma cells.” Mol Biol Cell 16(1): 51–63.

    Article  PubMed  CAS  Google Scholar 

  • Ma, J., M. N. Pollak, et al. (1999). “Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3.” J Natl Cancer Inst 91(7): 620–5.

    Article  PubMed  CAS  Google Scholar 

  • Ma, Y. and L. M. Hendershot (2004). “The role of the unfolded protein response in tumour development: friend or foe?” Nat Rev Cancer 4(12): 966–77.

    Article  PubMed  CAS  Google Scholar 

  • Manes, S., M. Llorente, et al. (1999). “The matrix metalloproteinase-9 regulates the insulin-like growth factor-triggered autocrine response in DU-145 carcinoma cells.” J Biol Chem 274(11): 6935–45.

    Article  PubMed  CAS  Google Scholar 

  • Manes, S., E. Mira, et al. (1997). “Identification of insulin-like growth factor-binding protein-1 as a potential physiological substrate for human stromelysin-3.” J Biol Chem 272(41): 25706–12.

    Article  PubMed  CAS  Google Scholar 

  • Manousos, O., J. Souglakos, et al. (1999). “IGF-I and IGF-II in relation to colorectal cancer.” Int J Cancer 83(1): 15–7.

    Article  PubMed  CAS  Google Scholar 

  • Mantzoros, C. S., A. Tzonou, et al. (1997). “Insulin-like growth factor 1 in relation to prostate cancer and benign prostatic hyperplasia.” Br J Cancer 76(9): 1115–8.

    Article  PubMed  CAS  Google Scholar 

  • Maor, S. B., S. Abramovitch, et al. (2000). “BRCA1 suppresses insulin-like growth factor-I receptor promoter activity: potential interaction between BRCA1 and Sp1.” Mol Genet Metab 69(2): 130–6.

    Article  PubMed  CAS  Google Scholar 

  • Maor, S., A. Yosepovich et al. (2007). “Elevated insulin-like growth factor −1 receptor (IGF-1R) levels in primary breast tumors associated with BRCA1 mutations”. Cancer Lett 257(2):236–43.

    Article  PubMed  CAS  Google Scholar 

  • Marelli, M. M., R. M. Moretti, et al. (2006). “Insulin-like growth factor-I promotes migration in human androgen-independent prostate cancer cells via the alphavbeta3 integrin and PI3-K/Akt signaling.” Int J Oncol 28(3): 723–30.

    PubMed  CAS  Google Scholar 

  • Metalli, D., F. Lovat, et al. (2010). “The Insulin-Like Growth Factor Receptor I Promotes Motility and Invasion of Bladder Cancer Cells through Akt- and Mitogen-Activated Protein Kinase-Dependent Activation of Paxillin.” Am J Pathol.

    Google Scholar 

  • Meyer, G. E., E. Shelden, et al. (2001). “Insulin-like growth factor I stimulates motility in human neuroblastoma cells.” Oncogene 20(51): 7542–50.

    Article  PubMed  CAS  Google Scholar 

  • Miki, H. and T. Takenawa (2003). “Regulation of actin dynamics by WASP family proteins.” J Biochem 134(3): 309–13.

    Article  PubMed  CAS  Google Scholar 

  • Miller, T. W., M. Perez-Torres, et al. (2009). “Loss of Phosphatase and Tensin homologue deleted on chromosome 10 engages ErbB3 and insulin-like growth factor-I receptor signaling to ­promote antiestrogen resistance in breast cancer.” Cancer Res 69(10): 4192–201.

    Article  PubMed  CAS  Google Scholar 

  • Mira, E., S. Manes, et al. (1999). “Insulin-like growth factor I-triggered cell migration and invasion are mediated by matrix metalloproteinase-9.” Endocrinology 140(4): 1657–64.

    Article  PubMed  CAS  Google Scholar 

  • Mitchison, T. J. and L. P. Cramer (1996). “Actin-based cell motility and cell locomotion.” Cell 84(3): 371–9.

    Article  PubMed  CAS  Google Scholar 

  • Mitsiades, C.S, N.S. Mitsiades et al. (2004). “Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors.” Cancer Cell 5(3):221–30.

    Article  PubMed  CAS  Google Scholar 

  • Mitsiades, N., W. H. Yu, et al. (2001). “Matrix metalloproteinase-7-mediated cleavage of Fas ligand protects tumor cells from chemotherapeutic drug cytotoxicity.” Cancer Res 61(2): 577–81.

    PubMed  CAS  Google Scholar 

  • Miyashita, T., Y. Takeishi, et al. (2001). “Role of calcineurin in insulin-like growth factor-1-induced hypertrophy of cultured adult rat ventricular myocytes.” Jpn Circ J 65(9): 815–9.

    Article  PubMed  CAS  Google Scholar 

  • Moore, T., S. Carbajal, et al. (2008). “Reduced susceptibility to two-stage skin carcinogenesis in mice with low circulating insulin-like growth factor I levels.” Cancer Res 68(10): 3680–8.

    Article  PubMed  CAS  Google Scholar 

  • Moorehead, R. A., O. H. Sanchez, et al. (2003). “Transgenic overexpression of IGF-II induces spontaneous lung tumors: a model for human lung adenocarcinoma.” Oncogene 22(6): 853–7.

    Article  PubMed  CAS  Google Scholar 

  • Morali, O. G., V. Delmas, et al. (2001). “IGF-II induces rapid beta-catenin relocation to the nucleus during epithelium to mesenchyme transition.” Oncogene 20(36): 4942–50.

    Article  PubMed  CAS  Google Scholar 

  • Morris, J. K., L. M. George, et al. (2006). “Insulin-like growth factors and cancer: no role in screening. Evidence from the BUPA study and meta-analysis of prospective epidemiological studies.” Br J Cancer 95(1): 112–7.

    Article  PubMed  CAS  Google Scholar 

  • Mukohara, T., H. Shimada et al. (2009). “Sensitivity of breast cancer cell lines to the novel insulin-like growth factor-1 receptor (IGF-1R) inhibitor NVP-AEW541 is dependent on the level of IRS-1 expression Cancer Lett 282(1):14–24.

    Article  PubMed  CAS  Google Scholar 

  • Musaro, A., K. J. McCullagh, et al. (1999). “IGF-1 induces skeletal myocyte hypertrophy through calcineurin in association with GATA-2 and NF-ATc1.” Nature 400(6744): 581–5.

    Article  PubMed  CAS  Google Scholar 

  • Nakamura, M., S. Miyamoto, et al. (2005). “Matrix metalloproteinase-7 degrades all insulin-like growth factor binding proteins and facilitates insulin-like growth factor bioavailability.” Biochem Biophys Res Commun 333(3): 1011–6.

    Article  PubMed  CAS  Google Scholar 

  • Nanni, P., Nicoletti, G. et al (2010). High metastatic efficiency of human sarcoma cells in Rag2/γc double knockout mice provides a powerful test system for antimetastatic targeted therapy. European Journal of Cardiovascular prevention and rehabilitation 46 (3):659–68.

    CAS  Google Scholar 

  • Navab, R., C. Pedraza, et al. (2008). “Loss of responsiveness to IGF-I in cells with reduced cathepsin L expression levels.” Oncogene 27(37): 4973–85.

    Article  PubMed  CAS  Google Scholar 

  • Ng, E. H., C. Y. Ji, et al. (1998). “Altered serum levels of insulin-like growth-factor binding proteins in breast cancer patients.” Ann Surg Oncol 5(2): 194–201.

    Article  PubMed  CAS  Google Scholar 

  • Nishiya, N., W. B. Kiosses, et al. (2005). “An alpha4 integrin-paxillin-Arf-GAP complex restricts Rac activation to the leading edge of migrating cells.” Nat Cell Biol 7(4): 343–52.

    Article  PubMed  CAS  Google Scholar 

  • Nobes, C. and A. Hall (1994). “Regulation and function of the Rho subfamily of small GTPases.” Curr Opin Genet Dev 4(1): 77–81.

    Article  PubMed  CAS  Google Scholar 

  • Novosyadlyy, R., N. Kurshan, et al. (2008). “Insulin-like growth factor-I protects cells from ER stress-induced apoptosis via enhancement of the adaptive capacity of endoplasmic reticulum.” Cell Death Differ 15(8): 1304–17.

    Article  PubMed  CAS  Google Scholar 

  • Nussbaum, T., J. Samarin, et al. (2008). “Autocrine insulin-like growth factor-II stimulation of tumor cell migration is a progression step in human hepatocarcinogenesis.” Hepatology 48(1): 146–56.

    Article  PubMed  CAS  Google Scholar 

  • Ohira, T., R. M. Gemmill, et al. (2003). “WNT7a induces E-cadherin in lung cancer cells.” Proc Natl Acad Sci USA 100(18): 10429–34.

    Article  PubMed  CAS  Google Scholar 

  • Ohlsson, C., N. Kley, et al. (1998). “p53 regulates insulin-like growth factor-I (IGF-I) receptor expression and IGF-I-induced tyrosine phosphorylation in an osteosarcoma cell line: interaction between p53 and Sp1.” Endocrinology 139(3): 1101–7.

    Article  PubMed  CAS  Google Scholar 

  • Okawa, Y., T. Hideshima, et al. (2009). “SNX-2112, a selective Hsp90 inhibitor, potently inhibits tumor cell growth, angiogenesis, and osteoclastogenesis in multiple myeloma and other hematologic tumors by abrogating signaling via Akt and ERK.” Blood 113(4): 846–55.

    Article  PubMed  CAS  Google Scholar 

  • Olivo-Marston, S. E., S. D. Hursting, et al. (2009). “Genetic reduction of circulating insulin-like growth factor-1 inhibits azoxymethane-induced colon tumorigenesis in mice.” Mol Carcinog 48(12): 1071–6.

    Article  PubMed  CAS  Google Scholar 

  • Oshima, T., M. Akaike, et al. (2008). “Clinicopathological significance of the gene expression of matrix metalloproteinase-7, insulin-like growth factor-1, insulin-like growth factor-2 and insulin-like growth factor-1 receptor in patients with colorectal cancer: insulin-like growth factor-1 receptor gene expression is a useful predictor of liver metastasis from colorectal cancer.” Oncol Rep 20(2): 359–64.

    PubMed  CAS  Google Scholar 

  • Oyadomari, S. and M. Mori (2004). “Roles of CHOP/GADD153 in endoplasmic reticulum stress.” Cell Death Differ 11(4): 381–9.

    Article  PubMed  CAS  Google Scholar 

  • Palmqvist, R., G. Hallmans, et al. (2002). “Plasma insulin-like growth factor 1, insulin-like growth factor binding protein 3, and risk of colorectal cancer: a prospective study in northern Sweden.” Gut 50(5): 642–6.

    Article  PubMed  CAS  Google Scholar 

  • Pang, Y., B. Zheng, et al. (2007). “IGF-1 protects oligodendrocyte progenitors against TNFalpha-induced damage by activation of PI3K/Akt and interruption of the mitochondrial apoptotic pathway.” Glia 55(11): 1099–107.

    Article  PubMed  Google Scholar 

  • Papa, V., B. Gliozzo, et al. (1993). “Insulin-like growth factor-I receptors are overexpressed and predict a low risk in human breast cancer.” Cancer Res 53(16): 3736–40.

    PubMed  CAS  Google Scholar 

  • Párrizas, M., A Gazit et al. (1997). “Specific inhibition of insulin-like growth factor-1 and insulin receptor tyrosine kinase activity and biological function by tyrphostins.” Endocrinology 138(4):1427–33.

    Article  PubMed  Google Scholar 

  • Park, E.J., J.H. Lee et al. (2010). “Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression.” Cell 140(2):197–208.

    Article  PubMed  CAS  Google Scholar 

  • Park, I. H., E. Erbay, et al. (2005). “Skeletal myocyte hypertrophy requires mTOR kinase activity and S6K1.” Exp Cell Res 309(1): 211–9.

    Article  PubMed  CAS  Google Scholar 

  • Parsons, S. A., D. P. Millay, et al. (2004). “Genetic loss of calcineurin blocks mechanical overload-induced skeletal muscle fiber type switching but not hypertrophy.” J Biol Chem 279(25): 26192–200.

    Article  PubMed  CAS  Google Scholar 

  • Peinado, H., D. Olmeda, et al. (2007). “Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype?” Nat Rev Cancer 7(6): 415–28.

    Article  PubMed  CAS  Google Scholar 

  • Pennacchietti, S., P. Michieli, et al. (2003). “Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene.” Cancer Cell 3(4): 347–61.

    Article  PubMed  Google Scholar 

  • Perks,C.M, C. McCaig et al. (2000). “Differential insulin-like growth factor (IGF)- independent interactions of IGF binding protein-3 and IGF binding protein-5 on apoptosis in human breast cancer cells. Involvement of the mitochondria.” J Cell Biochem 80(2):248–58.

    Article  PubMed  CAS  Google Scholar 

  • Peruzzi, F., M. Prisco, et al. (1999). “Multiple signaling pathways of the insulin-like growth factor 1 receptor in protection from apoptosis.” Mol Cell Biol 19(10): 7203–15.

    PubMed  CAS  Google Scholar 

  • Peruzzi, F., M. Prisco, et al. (2001). “Anti-apoptotic signaling of the insulin-like growth factor-I receptor through mitochondrial translocation of c-Raf and Nedd4.” J Biol Chem 276(28): 25990–6.

    Article  PubMed  CAS  Google Scholar 

  • Petridou, E., P. Koukoulomatis, et al. (2003). “Endometrial cancer and the IGF system: a case-control study in Greece.” Oncology 64(4): 341–5.

    Article  PubMed  Google Scholar 

  • Petridou, E., Y. Papadiamantis, et al. (2000). “Leptin and insulin growth factor I in relation to breast cancer (Greece).” Cancer Causes Control 11(5): 383–8.

    Article  PubMed  CAS  Google Scholar 

  • Peyrat, J. P., J. Bonneterre, et al. (1988). “Presence and characterization of insulin-like growth factor 1 receptors in human benign breast disease.” Eur J Cancer Clin Oncol 24(9): 1425–31.

    Article  PubMed  CAS  Google Scholar 

  • Pietrzkowski Z., G. Mulholland et al. (1993). “Inhibition of growth of prostatic cancer cell lines by peptide analogues of insulin-like growth factor 1.” Cancer Res 53(5):1102–6.

    PubMed  CAS  Google Scholar 

  • Pollak, M., M. J. Blouin, et al. (2001). “Reduced mammary gland carcinogenesis in transgenic mice expressing a growth hormone antagonist.” Br J Cancer 85(3): 428–30.

    Article  PubMed  CAS  Google Scholar 

  • Pollak, M. N., J. F. Perdue, et al. (1987). “Presence of somatomedin receptors on primary human breast and colon carcinomas.” Cancer Lett 38(1–2): 223–30.

    Article  PubMed  CAS  Google Scholar 

  • Pollak, M. N., C. Polychronakos, et al. (1988). “Characterization of insulin-like growth factor I (IGF-I) receptors of human breast cancer cells.” Biochem Biophys Res Commun 154(1): 326–31.

    Article  PubMed  CAS  Google Scholar 

  • Pollak, M.N. and A.V. Schally (1998). “Mechanisms of antineoplastic action of somatostatin analogs.” Proc Soc Exp Biol Med 217(2):143–52.

    PubMed  CAS  Google Scholar 

  • Poulaki, V., C. S. Mitsiades, et al. (2003). “Regulation of vascular endothelial growth factor expression by insulin-like growth factor I in thyroid carcinomas.” J Clin Endocrinol Metab 88(11): 5392–8.

    Article  PubMed  CAS  Google Scholar 

  • Powell, W. C., B. Fingleton, et al. (1999). “The metalloproteinase matrilysin proteolytically generates active soluble Fas ligand and potentiates epithelial cell apoptosis.” Curr Biol 9(24): 1441–7.

    Article  PubMed  CAS  Google Scholar 

  • Qiang, Y. W., L. Yao, et al. (2004). “Insulin-like growth factor I induces migration and invasion of human multiple myeloma cells.” Blood 103(1): 301–8.

    Article  PubMed  CAS  Google Scholar 

  • Quinn, L. S., B. G. Anderson, et al. (2007). “Muscle-specific overexpression of the type 1 IGF receptor results in myoblast-independent muscle hypertrophy via PI3K, and not calcineurin, signaling.” Am J Physiol Endocrinol Metab 293(6): E1538-51.

    Article  PubMed  CAS  Google Scholar 

  • Raftopoulou, M. and A. Hall (2004). “Cell migration: Rho GTPases lead the way.” Dev Biol 265(1): 23–32.

    Article  PubMed  CAS  Google Scholar 

  • Railo, M. J., K. von Smitten, et al. (1994). “The prognostic value of insulin-like growth factor-I in breast cancer patients. Results of a follow-up study on 126 patients.” Eur J Cancer 30A(3): 307–11.

    Article  PubMed  CAS  Google Scholar 

  • Ramsey, M. M., R. L. Ingram, et al. (2002). “Growth hormone-deficient dwarf animals are resistant to dimethylbenzanthracine (DMBA)-induced mammary carcinogenesis.” Endocrinology 143(10): 4139–42.

    Article  PubMed  CAS  Google Scholar 

  • Remacle-Bonnet, M., F. Garrouste, et al. (2005). “Membrane rafts segregate pro- from anti-apoptotic insulin-like growth factor-I receptor signaling in colon carcinoma cells stimulated by members of the tumor necrosis factor superfamily.” Am J Pathol 167(3): 761–73.

    Article  PubMed  CAS  Google Scholar 

  • Renehan, A. G., M. Zwahlen, et al. (2004). “Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis.” Lancet 363(9418): 1346–53.

    Article  PubMed  CAS  Google Scholar 

  • Rinaldi, S., P. H. Peeters, et al. (2006). “IGF-I, IGFBP-3 and breast cancer risk in women: The European Prospective Investigation into Cancer and Nutrition (EPIC).” Endocr Relat Cancer 13(2): 593–605.

    Article  PubMed  CAS  Google Scholar 

  • Rosenthal, S. M. and Z. Q. Cheng (1995). “Opposing early and late effects of insulin-like growth factor I on differentiation and the cell cycle regulatory retinoblastoma protein in skeletal myoblasts.” Proc Natl Acad Sci USA 92(22): 10307–11.

    Article  PubMed  CAS  Google Scholar 

  • Ross, M.H. and G. Bras (1971). “Lasting influence of early caloric restriction on prevalence of neoplasms in the rat.” J Natl Cancer Inst 47(5):1095–113.

    PubMed  CAS  Google Scholar 

  • Ruan, W. and D. L. Kleinberg (1999). “Insulin-like growth factor I is essential for terminal end bud formation and ductal morphogenesis during mammary development.” Endocrinology 140(11): 5075–81.

    Article  PubMed  CAS  Google Scholar 

  • Sachdev, D., J. S. Hartell, et al. (2004). “A dominant negative type I insulin-like growth factor receptor inhibits metastasis of human cancer cells.” J Biol Chem 279(6): 5017–24.

    Article  PubMed  CAS  Google Scholar 

  • Sachdev, P., Y. X. Jiang, et al. (2001). “Differential requirement for Rho family GTPases in an oncogenic insulin-like growth factor-I receptor-induced cell transformation.” J Biol Chem 276(28): 26461–71.

    Article  PubMed  CAS  Google Scholar 

  • Sah, V. P., T. M. Seasholtz, et al. (2000). “The role of Rho in G protein-coupled receptor signal transduction.” Annu Rev Pharmacol Toxicol 40: 459–89.

    Article  PubMed  CAS  Google Scholar 

  • Sakatani, T., A. Kaneda, et al. (2005). “Loss of imprinting of Igf2 alters intestinal maturation and tumorigenesis in mice.” Science 307(5717): 1976–8.

    Article  PubMed  CAS  Google Scholar 

  • Salani, B., L. Briatore, et al. (2008). “Caveolin-1 down-regulation inhibits insulin-like growth factor-I receptor signal transduction in H9C2 rat cardiomyoblasts.” Endocrinology 149(2): 461–5.

    Article  PubMed  CAS  Google Scholar 

  • Schakman, O., S. Kalista, et al. (2008). “Role of Akt/GSK-3beta/beta-catenin transduction pathway in the muscle anti-atrophy action of insulin-like growth factor-I in glucocorticoid-treated rats.” Endocrinology 149(8): 3900–8.

    Article  PubMed  CAS  Google Scholar 

  • Schernhammer, E. S., J. M. Holly, et al. (2006). “Insulin-like growth factor-I, its binding proteins (IGFBP-1 and IGFBP-3), and growth hormone and breast cancer risk in The Nurses Health Study II.” Endocr Relat Cancer 13(2): 583–92.

    Article  PubMed  CAS  Google Scholar 

  • Schroder, M. and R. J. Kaufman (2005). “ER stress and the unfolded protein response.” Mutat Res 569(1–2): 29–63.

    PubMed  Google Scholar 

  • Semenza, G. L. (2003). “Targeting HIF-1 for cancer therapy.” Nat Rev Cancer 3(10): 721–32.

    Article  PubMed  CAS  Google Scholar 

  • Semsarian, C., M. J. Wu, et al. (1999). “Skeletal muscle hypertrophy is mediated by a Ca2+−dependent calcineurin signalling pathway.” Nature 400(6744): 576–81.

    Article  PubMed  CAS  Google Scholar 

  • Severi, G., H. A. Morris, et al. (2006). “Circulating insulin-like growth factor-I and binding protein-3 and risk of prostate cancer.” Cancer Epidemiol Biomarkers Prev 15(6): 1137–41.

    Article  PubMed  CAS  Google Scholar 

  • Shi, R., H. Yu, et al. (2004). “IGF-I and breast cancer: a meta-analysis.” Int J Cancer 111(3): 418–23.

    Article  PubMed  CAS  Google Scholar 

  • Shields, S. K., C. Nicola, et al. (2007). “Rho guanosine 5’-triphosphatases differentially regulate insulin-like growth factor I (IGF-I) receptor-dependent and -independent actions of IGF-II on human trophoblast migration.” Endocrinology 148(10): 4906–17.

    Article  PubMed  CAS  Google Scholar 

  • Shimizu, C., T. Hasegawa, et al. (2004). “Expression of insulin-like growth factor 1 receptor in primary breast cancer: immunohistochemical analysis.” Hum Pathol 35(12): 1537–42.

    Article  PubMed  CAS  Google Scholar 

  • Skobe, M., T. Hawighorst, et al. (2001). “Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis.” Nat Med 7(2): 192–8.

    Article  PubMed  CAS  Google Scholar 

  • Srinivasan, S., M. Ohsugi, et al. (2005). “Endoplasmic reticulum stress-induced apoptosis is partly mediated by reduced insulin signaling through phosphatidylinositol 3-kinase/Akt and increased glycogen synthase kinase-3beta in mouse insulinoma cells.” Diabetes 54(4): 968–75.

    Article  PubMed  CAS  Google Scholar 

  • Stacker, S. A., C. Caesar, et al. (2001). “VEGF-D promotes the metastatic spread of tumor cells via the lymphatics.” Nat Med 7(2): 186–91.

    Article  PubMed  CAS  Google Scholar 

  • Stattin, P., A. Bylund, et al. (2000). “Plasma insulin-like growth factor-I, insulin-like growth factor-binding proteins, and prostate cancer risk: a prospective study.” J Natl Cancer Inst 92(23): 1910–7.

    Article  PubMed  CAS  Google Scholar 

  • Stitt, T. N., D. Drujan, et al. (2004). “The IGF-1/PI3K/Akt pathway prevents expression of muscle atrophy-induced ubiquitin ligases by inhibiting FOXO transcription factors.” Mol Cell 14(3): 395–403.

    Article  PubMed  CAS  Google Scholar 

  • Stoeltzing, O., W. Liu, et al. (2007). “Regulation of cyclooxygenase-2 (COX-2) expression in human pancreatic carcinoma cells by the insulin-like growth factor-I receptor (IGF-IR) system.” Cancer Lett 258(2): 291–300.

    Article  PubMed  CAS  Google Scholar 

  • Stracke, M. L., J. D. Engel, et al. (1989). “The type I insulin-like growth factor receptor is a motility receptor in human melanoma cells.” J Biol Chem 264(36): 21544–9.

    PubMed  CAS  Google Scholar 

  • Sugumar, A., Y. C. Liu, et al. (2004). “Insulin-like growth factor (IGF)-I and IGF-binding protein 3 and the risk of premenopausal breast cancer: a meta-analysis of literature.” Int J Cancer 111(2): 293–7.

    Article  PubMed  CAS  Google Scholar 

  • Surmacz, E. (2003) “Growth factor receptors as therapeutic targets: strategies to inhibit the insulin-like growth factor I receptor.” Oncogene 22(42): 6589–97.

    Article  PubMed  CAS  Google Scholar 

  • Suwa, H., G. Ohshio, et al. (1998). “Overexpression of the rhoC gene correlates with progression of ductal adenocarcinoma of the pancreas.” Br J Cancer 77(1): 147–52.

    Article  PubMed  CAS  Google Scholar 

  • Szereday Z., A.V. Schally et al. (2003). “Effective treatment of H838 human non-small cell lung carcinoma with a targeted cytotoxic somatostatin analog, AN-238.” Int J Oncol 22(5): 1141–6.

    PubMed  CAS  Google Scholar 

  • Takeichi, M. (1991). “Cadherin cell adhesion receptors as a morphogenetic regulator.” Science 251(5000): 1451–5.

    Article  PubMed  CAS  Google Scholar 

  • Takenawa, T. and H. Miki (2001). “WASP and WAVE family proteins: key molecules for rapid rearrangement of cortical actin filaments and cell movement.” J Cell Sci 114(Pt 10): 1801–9.

    PubMed  CAS  Google Scholar 

  • Tanaka, H., M. Yamamoto, et al. (2006). “Hypoxia-independent overexpression of hypoxia-inducible factor 1alpha as an early change in mouse hepatocarcinogenesis.” Cancer Res 66(23): 11263–70.

    Article  PubMed  CAS  Google Scholar 

  • Tanno, S., S. Tanno, et al. (2001). “AKT activation up-regulates insulin-like growth factor I receptor expression and promotes invasiveness of human pancreatic cancer cells.” Cancer Res 61(2): 589–93.

    PubMed  CAS  Google Scholar 

  • Taya, S., N. Inagaki, et al. (2001). “Direct interaction of insulin-like growth factor-1 receptor with leukemia-associated RhoGEF.” J Cell Biol 155(5): 809–20.

    Article  PubMed  CAS  Google Scholar 

  • Tennant, M. K., J. B. Thrasher, et al. (1996). “Protein and messenger ribonucleic acid (mRNA) for the type 1 insulin-like growth factor (IGF) receptor is decreased and IGF-II mRNA is increased in human prostate carcinoma compared to benign prostate epithelium.” J Clin Endocrinol Metab 81(10): 3774–82.

    Article  PubMed  CAS  Google Scholar 

  • Thimmaiah, K. N., J. B. Easton, et al. (2010). “Protection from rapamycin-induced apoptosis by insulin-like growth factor-I is partially dependent on protein kinase C signaling.” Cancer Res 70(5): 2000–9.

    Article  PubMed  CAS  Google Scholar 

  • Tomizawa, M., F. Shinozaki, et al.(2010). “Insulin-like growth factor-I receptor in proliferation and motility of pancreatic cancer.” World J Gastroenterol 16(15): 1854–8.

    Article  PubMed  CAS  Google Scholar 

  • Toniolo, P., P. F. Bruning, et al. (2000). “Serum insulin-like growth factor-I and breast cancer.” Int J Cancer 88(5): 828–32.

    Article  PubMed  CAS  Google Scholar 

  • Toyoshima, K., N. Ito, et al. (1971). “Tissue culture of urinary bladder tumor induced in a rat by N-butyl-N-(−4-hydroxybutyl)nitrosamine: establishment of cell line, Nara Bladder Tumor II.” J Natl Cancer Inst 47(5): 979–85.

    PubMed  CAS  Google Scholar 

  • Tsai, W. C., Y. C. Chao, et al. (2006). “Increasing EMMPRIN and matriptase expression in hepatocellular carcinoma: tissue microarray analysis of immunohistochemical scores with clinicopathological parameters.” Histopathology 49(4): 388–95.

    Article  PubMed  Google Scholar 

  • Tseng, Y. H., K. Ueki, et al. (2002). “Differential roles of insulin receptor substrates in the anti-apoptotic function of insulin-like growth factor-1 and insulin.” J Biol Chem 277(35): 31601–11.

    Article  PubMed  CAS  Google Scholar 

  • Tsukatani, Y., K. Suzuki, et al. (1997). “Loss of density-dependent growth inhibition and dissociation of alpha-catenin from E-cadherin.” J Cell Physiol 173(1): 54–63.

    Article  PubMed  CAS  Google Scholar 

  • Ueda, S., H. Tsuda, et al. (2006). “Alternative tyrosine phosphorylation of signaling kinases according to hormone receptor status in breast cancer overexpressing the insulin-like growth factor receptor type 1.” Cancer Sci 97(7): 597–604.

    Article  PubMed  CAS  Google Scholar 

  • van der Kallen, C. J., M. M. van Greevenbroek, et al. (2009). “Endoplasmic reticulum stress-induced apoptosis in the development of diabetes: is there a role for adipose tissue and liver?” Apoptosis 14(12): 1424–34.

    Article  PubMed  CAS  Google Scholar 

  • van Golen, C. M., T. S. Schwab, et al. (2006). “Insulin-like growth factor-I receptor expression regulates neuroblastoma metastasis to bone.” Cancer Res 66(13): 6570–8.

    Article  PubMed  Google Scholar 

  • van Golen, K. L., L. Bao, et al. (2002). “Reversion of RhoC GTPase-induced inflammatory breast cancer phenotype by treatment with a farnesyl transferase inhibitor.” Mol Cancer Ther 1(8): 575–83.

    PubMed  Google Scholar 

  • van Noord P.A. (2004). “Breast cancer and the brain: a neurodevelopmental hypothesis to explain the opposing effects of caloric deprivation during the Dutch famine of 1944–1945 on breast cancer and its risk factors.” J Nutr 134(12 Suppl): 3399S–3406S.

    PubMed  Google Scholar 

  • Van Saun M.N., I.K. Lee et al. (2009). “High fat diet induced hepatic steatosis establishes a permissive microenvironment for colorectal metastases and promotes primary dysplasia in a murine model.” Am J Pathol 175(1): 355–64.

    Article  Google Scholar 

  • Vasilcanu D., A. Girnita et al. (2004). “The cyclolignan PPP induces activation loop- specific inhibition of tyrosine phosphorylation of the insulin-like growth factor-1 receptor. Link to the phosphatidyl inositol-3 kinase/Akt apoptotic pathway.” Oncogene 23(47): 7854–62.

    Article  PubMed  CAS  Google Scholar 

  • Vasioukhin, V., C. Bauer, et al. (2000). “Directed actin polymerization is the driving force for epithelial cell-cell adhesion.” Cell 100(2): 209–19.

    Article  PubMed  CAS  Google Scholar 

  • Vousden, K. H. (2000). “p53: death star.” Cell 103(5): 691–4.

    Article  PubMed  CAS  Google Scholar 

  • Vyas, D. R., E. E. Spangenburg, et al. (2002). “GSK-3beta negatively regulates skeletal myotube hypertrophy.” Am J Physiol Cell Physiol 283(2): C545–51.

    PubMed  CAS  Google Scholar 

  • Wahner Hendrickson A.E., P. Haluska et al (2009). “Expression of insulin receptor isoform A and insulin-like growth factor-1 receptor in human acute myelogenous leukemia: effect of the dual-receptor inhibitor BMS-536924 in vitro.” Cancer Res 69(19): 7635–43. In press.

    Google Scholar 

  • Wan X., B. Harkavy et al. (2006). “Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism.” Oncogene 26(13): 1932–40.

    Article  PubMed  CAS  Google Scholar 

  • Wang, F., P. Herzmark, et al. (2002). “Lipid products of PI(3)Ks maintain persistent cell polarity and directed motility in neutrophils.” Nat Cell Biol 4(7): 513–8.

    Article  PubMed  CAS  Google Scholar 

  • Wang, L., Y. Y. Shao, et al. (2010). “Thyroid hormone-mediated growth and differentiation of growth plate chondrocytes involves IGF-1 modulation of beta-catenin signaling.” J Bone Miner Res.

    Google Scholar 

  • Warshamana-Greene G.S., J. Litz et al. (2004). “The insulin-like growth factor-I (IGF-I) receptor kinase inhibitor NVP-ADW742, in combination with STI571, delineates a spectrum of dependence of small cell lung cancer on IGF-I and stem cell factor signaling.” Mol Cancer Ther 3(5): 527–35.

    PubMed  CAS  Google Scholar 

  • Weiner, O. D., P. O. Neilsen, et al. (2002). “A PtdInsP(3)- and Rho GTPase-mediated positive feedback loop regulates neutrophil polarity.” Nat Cell Biol 4(7): 509–13.

    Article  PubMed  CAS  Google Scholar 

  • Werner, H., G. G. Re, et al. (1993). “Increased expression of the insulin-like growth factor I receptor gene, IGF1R, in Wilms tumor is correlated with modulation of IGF1R promoter activity by the WT1 Wilms tumor gene product.” Proc Natl Acad Sci USA 90(12): 5828–32.

    Article  PubMed  CAS  Google Scholar 

  • Werner, H., F. J. Rauscher, et al. (1994). “Transcriptional repression of the insulin-like growth factor I receptor (IGF-I-R) gene by the tumor suppressor WT1 involves binding to sequences both upstream and downstream of the IGF-I-R gene transcription start site.” J Biol Chem 269(17): 12577–82.

    PubMed  CAS  Google Scholar 

  • Werner, H., E. Karnieli, et al. (1996). “Wild-type and mutant p53 differentially regulate transcription of the insulin-like growth factor I receptor gene.” Proc Natl Acad Sci USA 93(16): 8318–23.

    Article  PubMed  CAS  Google Scholar 

  • Whitelock, J. M., A. D. Murdoch, et al. (1996). “The degradation of human endothelial cell-derived perlecan and release of bound basic fibroblast growth factor by stromelysin, collagenase, plasmin, and heparanases.” J Biol Chem 271(17): 10079–86.

    Article  PubMed  CAS  Google Scholar 

  • Wilker, E., D. Bol, et al. (1999). “Enhancement of susceptibility to diverse skin tumor promoters by activation of the insulin-like growth factor-1 receptor in the epidermis of transgenic mice.” Mol Carcinog 25(2): 122–31.

    Article  PubMed  CAS  Google Scholar 

  • Wolf S., J. Lorenz et al. (2010). “Treatment of biliary tract cancer with NVP-AEW541: mechanisms of action and resistance.” World J Gastroenterol 16(2): 156–66.

    Article  PubMed  CAS  Google Scholar 

  • Wolk, A., C. S. Mantzoros, et al. (1998). “Insulin-like growth factor 1 and prostate cancer risk: a population-based, case-control study.” J Natl Cancer Inst 90(12): 911–5.

    Article  PubMed  CAS  Google Scholar 

  • Woodson, K., J. A. Tangrea, et al. (2003). “Serum insulin-like growth factor I: tumor marker or etiologic factor? A prospective study of prostate cancer among Finnish men.” Cancer Res 63(14): 3991–4.

    PubMed  CAS  Google Scholar 

  • Wu, Y., S. Yakar, et al. (2002). “Circulating insulin-like growth factor-I levels regulate colon cancer growth and metastasis.” Cancer Res 62(4): 1030–5.

    PubMed  CAS  Google Scholar 

  • Wu, Y., K. Cui, et al. (2003). “Reduced circulating insulin-like growth factor I levels delay the onset of chemically and genetically induced mammary tumors.” Cancer Res 63(15): 4384–8.

    PubMed  CAS  Google Scholar 

  • Wu, Y., P. Brodt, et al. (2010)”Insulin-like growth factor-I regulates the liver microenvironment in obese mice and promotes liver metastasis.” Cancer Res 70(1): 57–67.

    Google Scholar 

  • Xu, J., D. Rodriguez, et al. (2001). “Proteolytic exposure of a cryptic site within collagen type IV is required for angiogenesis and tumor growth in vivo.” J Cell Biol 154(5): 1069–79.

    Article  PubMed  CAS  Google Scholar 

  • Yamaguchi, H., M. Shiraishi, et al. (2009). “MARCKS regulates lamellipodia formation induced by IGF-I via association with PIP2 and beta-actin at membrane microdomains.” J Cell Physiol 220(3): 748–55.

    Article  PubMed  CAS  Google Scholar 

  • Yamazaki, D., S. Kurisu, et al. (2005). “Regulation of cancer cell motility through actin reorganization.” Cancer Sci 96(7): 379–86.

    Article  PubMed  CAS  Google Scholar 

  • Yang, X. F., W. G. Beamer, et al. (1996). “Reduced growth of human breast cancer xenografts in hosts homozygous for the lit mutation.” Cancer Res 56(7): 1509–11.

    PubMed  CAS  Google Scholar 

  • Yao, H., E. J. Dashner, et al. (2006). “RhoC GTPase is required for PC-3 prostate cancer cell invasion but not motility.” Oncogene 25(16): 2285–96.

    Article  PubMed  CAS  Google Scholar 

  • Ye, P., Q. Hu, et al. (2010) “beta-catenin mediates insulin-like growth factor-I actions to promote cyclin D1 mRNA expression, cell proliferation and survival in oligodendroglial cultures.” Glia.

    Google Scholar 

  • Yu, H. and T. Rohan (2000). “Role of the insulin-like growth factor family in cancer development and progression.” J Natl Cancer Inst 92(18): 1472–89.

    Article  PubMed  CAS  Google Scholar 

  • Yu, H., M. R. Spitz, et al. (1999). “Plasma levels of insulin-like growth factor-I and lung cancer risk: a case-control analysis.” J Natl Cancer Inst 91(2): 151–6.

    Article  PubMed  CAS  Google Scholar 

  • Yuen, J. S., M. E. Cockman, et al. (2007). “The VHL tumor suppressor inhibits expression of the IGF1R and its loss induces IGF1R upregulation in human clear cell renal carcinoma.” Oncogene 26(45): 6499–508.

    Article  PubMed  CAS  Google Scholar 

  • Zhang, D., M. Bar-Eli et al (2004). Dual regulation of MMP-2 Expression by the Type 1 insulin-like Growth Factor Receptor. Journal Biol Chem 279: 19683–19690.

    Article  CAS  Google Scholar 

  • Zhang, X. and D. Yee (2002). “Insulin-like Growth Factor Binding Protein-1 (IGFBP-1) inhibits Breast Cancer Cell Motility”. Cancer Res 62: 4369–75.

    PubMed  CAS  Google Scholar 

  • Zhang, X., S. Kamaraju, et al. (2004). “Motility response to insulin-like growth factor-I (IGF-I) in MCF-7 cells is associated with IRS-2 activation and integrin expression.” Breast Cancer Res Treat 83(2): 161–70.

    Article  PubMed  CAS  Google Scholar 

  • Zhang, X., M. Lin, et al. (2005). “Multiple signaling pathways are activated during insulin-like growth factor-I (IGF-I) stimulated breast cancer cell migration.” Breast Cancer Res Treat 93(2): 159–68.

    Article  PubMed  CAS  Google Scholar 

  • Zhao, H., J. Dupont, et al. (2004). “PTEN inhibits cell proliferation and induces apoptosis by downregulating cell surface IGF-IR expression in prostate cancer cells.” Oncogene 23(3): 786–94.

    Article  PubMed  CAS  Google Scholar 

  • Zhao, H., H. B. Grossman, et al. (2003). “Plasma levels of insulin-like growth factor-1 and binding protein-3, and their association with bladder cancer risk.” J Urol 169(2): 714–7.

    Article  PubMed  CAS  Google Scholar 

  • Zhau, H. E., V. Odero-Marah, et al. (2008). “Epithelial to mesenchymal transition (EMT) in human prostate cancer: lessons learned from ARCaP model.” Clin Exp Metastasis 25(6): 601–10.

    Article  PubMed  CAS  Google Scholar 

  • Zhong, H., K. Chiles, et al. (2000). “Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics.” Cancer Res 60(6): 1541–5.

    PubMed  CAS  Google Scholar 

  • Zou, C. G., X. Z. Cao, et al. (2009). “The molecular mechanism of endoplasmic reticulum stress-induced apoptosis in PC-12 neuronal cells: the protective effect of insulin-like growth factor I.” Endocrinology 150(1): 277–85.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Endocrinology, Diabetes and Bone Diseases, The Samuel Bronfman Department of Medicine, Mount Sinai School of Medicine, New York, NY, USA

    Rosalyn D. Ferguson, Nyosha Alikhani, Archana Vijayakumar, Yvonne Fierz, Dara Cannata & Shoshana Yakar

Authors
  1. Rosalyn D. Ferguson
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Nyosha Alikhani
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Archana Vijayakumar
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yvonne Fierz
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Dara Cannata
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Shoshana Yakar
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Shoshana Yakar .

Editor information

Editors and Affiliations

  1. , Department of Medicine, Mount Sinai School of Medicine, 1 Gustave L. Levy Place, NEW YORK, 10029, USA

    Derek LeRoith

Rights and permissions

Reprints and permissions

Copyright information

© 2012 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Ferguson, R.D., Alikhani, N., Vijayakumar, A., Fierz, Y., Cannata, D., Yakar, S. (2012). IGF-1 Cellular Action and its Relationship to Cancer: Evidence from in Vitro and in Vivo Studies. In: LeRoith, D. (eds) Insulin-like Growth Factors and Cancer. Cancer Drug Discovery and Development. Springer, Boston, MA. https://doi.org/10.1007/978-1-4614-0598-6_6

Download citation

  • DOI: https://doi.org/10.1007/978-1-4614-0598-6_6

  • Published:

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4614-0597-9

  • Online ISBN: 978-1-4614-0598-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation